Video
Dr. Eure on BPH medications and increased risk of heart failure
Author(s):
Video Player is loading.
Gregg Eure, MD, FACS, Urology of Virginia, discusses the increased of heart failure associated with medications for the treatment of patients with benign prostatic hyperplasia (BPH). A recently published study showed an increased risk of cardiac failure in men with BPH and exposure to 5-alpha reductase inhibitors and/or α-blockers.
Newsletter
Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.
Related Videos
Kevin T. McVary, MD, FACS, discusses the expanded label for Rezum in BPH
Amy Krambeck, MD, on considerations for building clinical programs in endourology
Connor Forbes, MD, on trends in surgical procedures for BPH
Dean Elterman, MD, on the shift toward personalized care in BPH
Dean Elterman, MD, shares 3-year data on Zenflow Spring System for BPH
Adoption of New Treatment Modalities to Treat BPH
BPH: Strategies for Guiding Patients From Medication to Intervention
Impact of Robotic Procedures and Apps on Clinic Efficiency
Amy Krambeck, MD, on innovation and building strong programs in endourology
BPH Treatment and Impact on Sexual Health
Related Content
